DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)

Transcriptomal Analysis of Peripheral Blood and Skeletal Muscle in Patients Undergoing CRT Using Oligonucleotide Arrays

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00600392

Acronym

Medusa PH

Enrollment

Registered

2008-01-25

Start date

2006-01-31

Completion date

2011-12-31

Last updated

2016-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy (Ischemic or Non-Ischemic)

Brief summary

Genes expressing inflammatory cytokines (TNF- alpha, IL1 etc) and genes involved in apoptosis (Caspase 3, Bax, Bcl-2, Fas) are dysregulated in the skeletal muscles of the patients who have muscle wasting and decreased exercise capacity with CHF. Patients who show benefit from CRT may also show reversal of the inflammatory/apoptotic cascade that accompanies CHF and these patients may be the ones who benefit the most from CRT

Detailed description

1\. The general objective of this study is to: 1. To identify the molecular pathways that may be altered in the blood and skeletal muscles of the patients undergoing CRT by using transcriptional analysis of the blood and skeletal muscle in these patients 2. To identify objective measurable molecular signals, using gene expression profiling, that correlate with clinical improvement in patients undergoing CRT. 3. To identify the molecular profile of patients who are most likely to benefit from CRT with improvement of exercise capacity and reversal of cardiac cachexia. 4. To identify biochemical pathways involved in cardiac cachexia. 5. To identify genes involved in positive remodeling and reversal of apoptotic cascade in the skeletal muscle.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with poor LV function and an EF of ≤35% * Patients who are symptomatic with Class II or Class III heart failure on optimal medical therapy. * Patients with EKG showing QRS duration of greater than 120 ms and meet criteria for Bi-ventricular ICD implantation.

Exclusion criteria

* Patients with other co-morbid conditions which could contribute to cachexia, such as end stage renal disease, ongoing malignancy, chronic or acute liver failure, age greater than 80yrs. * Patients who are unable to walk and are wheelchair bound or need assistance to walk for reasons other than CHF. * Patients with muscular dystrophies and myopathies. * Patients with untreated hyper or hypothyroidism. * Patients on Dialysis. * Patients with recent (\<12 weeks) revascularization. * Patients with recent (\<12 weeks) myocardial infarction.

Design outcomes

Primary

Measure	Time frame
Shift of the muscle transcriptome away from Apoptosis/Inflammation. Reversal of active apoptosis in skeletal muscle.Quality of life assessment(Minn.HF Ques) Exercise capacity (6 min walk).	6 months

Secondary

Measure	Time frame
Improved LV synchrony as determined by TDI, Decrease in blood markers of inflammation and Oxidative stress and catabolism.	6 months

Countries

United States

Outcome results